Ten years ago, Cancer Research published a translational science report by researchers in France describing the relationship between genetics and outcome for patients with metastatic colorectal cancer treated with the newest targeted therapy cetuximab. Li evre and colleagues studied 30 patients and made a seminal observation correlating ras mutation to cetuximab failure that has guided therapy in colorectal cancer ever since, and that could arguably be credited with kicking off a new era in precision medicine by identifying a critical biomarker that was not simply an activating mutation in the drug's target (1) . The role of ras mutation in colorectal cancer had been appreciated for some time. In two seminal research manuscripts published in the New England Journal of Medicine (1987) and Nature (1988), Johannes Bos, Eric Fearon, and Bert Volgelstein and colleagues from the Netherlands described the prevalence of ras mutations as well as the basic concepts of oncogene and tumor suppression alterations directing the tumorigenesis process in the colon (2, 3) .
The small New York-based biotech company, ImClone Systems, developed a chimeric blocking mAb to EGFR for cancer therapy. Leading indications included head and neck cancer and colon cancer, based on early clinical activity and literature regarding EGFR prevalence in these indications. Therefore, investigation of EGFR expression as a predictor of response was a natural first direction and investigators initially studied cetuximab only in EGFR IHC-positive patients (4, 5) . However, ultimately the IHC approach was demonstrated not robust enough to be used for selection (6) . Moroni and colleagues and others also investigated EGFR amplification and mutation as a predictor of response using small numbers of patients from different EGFR antibodies and treatment regimens, arriving at the conclusions that EGFR amplification by FISH of DNA had some statistically meaningful correlations and was worth further investigation in future trials (7) . In those studies, common mutations in KRAS exon 2, PI3KCA, and BRAF were assessed but not identified as significant. In hindsight, this conclusion likely had to do with the serendipity of the small cohort of patients analyzed, as they were assembled from multiple trials. However, the manuscript highlighted by Cancer Research in this commentary as one of the more significant historical publications in the journal convincingly showed a meaningful correlation between KRAS mutations and cetuximab failure using data from three hospitals that participated in phase II studies (1) . Li evre and colleagues reported 43% KRAS mutation, which is consistent with previous studies of colorectal cancer, and 10% of EGFR amplification, which was also closer to previous reports. Li evre and colleagues' prevalence data differed from the previous report by Moroni and colleagues (7) that had reported 9 of 31 patients assessed by FISH contained amplified EGFR of 3 copies or more, and 10 of 31 patients had Kras exon 2 mutations, of which 8 were nonresponders. In retrospect, a significant difference can be seen in the copy number used to call a patient EGFR amplified. Li evre and colleagues used 6 copies of EGFR as their cutoff, and those patients did see benefit from cetuximab, but so did other patients. The discrepancy with the Moroni and colleagues' (7) study with respect to KRAS mutation prevalence could contribute to why they arrived at different conclusions for Kras.
On the basis of the report of Li evre and colleagues (1) and follow-up studies by the same group (8) and others (9), retrospective biomarker analysis was performed from multiple ongoing and future colorectal clinical trials with anti-EGFR antibodies. Ultimately, assessment of KRAS mutations in the patients from phase III trials confirmed the negative correlation between KRAS exon 2 mutations and benefit from anti-EGFR antibody therapy. This overwhelming volume of data was sufficient for the FDA to retrospectively change the label of cetuximab (Erbitux) and panitumumab (Vectibix) to require KRAS exon 2 wild-type status as prerequisite for treatment of colorectal cancer in 2009. Since this time the analysis of mutations and clinical benefit has continued and expanded in recent years to assess mutations in all isoforms and exons of Ras and other key signaling pathways. A compilation of metadata from 22 studies that include 2,395 patients identified additional mutations in KRAS exons 3 and 4, NRAS, BRA, PI3KCA, and PTEN as having a negative predictive value for therapeutic anti-EGFR antibodies in colorectal cancer (10) . At this time, both the United States and European Societies for Clinical Oncology (ASCO and ESMO) recommend expanded Ras testing for colorectal patients to help guide the choice of therapy (http://gicasym. org/asco-updates-guideline-include-testing-new-ras-mutations and http://www.ema.europa.eu/docs/en_GB/document_library/ Summary_of_opinion/human/000558/WC500155463.pdf).
The initial report by Li evre and colleagues (1) is an excellent example of how small translational, yet exploratory, studies have been and are critical to advances in patient care. In recent years, the FDA and other regulatory bodies have put in place a more systematic regulatory path for the inclusion of patient stratification based on diagnostics in drug labels. As these guidelines are relatively new and being tested, it is likely that the ultimate decisions for genetic testing or other diagnostic measures will further evolve in the coming years, adding to the already complex process of new drug approvals. However, as was the case in 2009 when Kras exon 2 testing became mandatory for anti-EGFR antibody use in colorectal cancer, the regulatory agencies will need to remain open-minded and nimble to take advantage of new knowledge and new technology associated with future diagnostics, as it is evermore imperative that patient selection become a standard component of oncology drug use in this age of personalized care.
